CN101103030B - 具有hm74a受体活性的药物 - Google Patents

具有hm74a受体活性的药物 Download PDF

Info

Publication number
CN101103030B
CN101103030B CN2005800114336A CN200580011433A CN101103030B CN 101103030 B CN101103030 B CN 101103030B CN 2005800114336 A CN2005800114336 A CN 2005800114336A CN 200580011433 A CN200580011433 A CN 200580011433A CN 101103030 B CN101103030 B CN 101103030B
Authority
CN
China
Prior art keywords
purine
dihydro
chloro
diketone
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800114336A
Other languages
English (en)
Chinese (zh)
Other versions
CN101103030A (zh
Inventor
伊凡·L·平托
沙扎德·S·拉曼
内维尔·H·尼科尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403282A external-priority patent/GB0403282D0/en
Priority claimed from GB0423562A external-priority patent/GB0423562D0/en
Priority claimed from GB0428375A external-priority patent/GB0428375D0/en
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN101103030A publication Critical patent/CN101103030A/zh
Application granted granted Critical
Publication of CN101103030B publication Critical patent/CN101103030B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2005800114336A 2004-02-14 2005-02-10 具有hm74a受体活性的药物 Expired - Fee Related CN101103030B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0403282.7 2004-02-14
GB0403282A GB0403282D0 (en) 2004-02-14 2004-02-14 Chemical compounds
GB0423562A GB0423562D0 (en) 2004-10-22 2004-10-22 Novel compounds
GB0423562.8 2004-10-22
GB0428375.0 2004-12-24
GB0428375A GB0428375D0 (en) 2004-12-24 2004-12-24 Novel compounds
PCT/EP2005/001449 WO2005077950A2 (en) 2004-02-14 2005-02-10 Medicaments with hm74a receptor activity

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN2010102007350A Division CN101863888B (zh) 2004-02-14 2005-02-10 具有hm74a受体活性的药物
CNA2008100992548A Division CN101274934A (zh) 2004-02-14 2005-02-10 具有hm74a受体活性的药物

Publications (2)

Publication Number Publication Date
CN101103030A CN101103030A (zh) 2008-01-09
CN101103030B true CN101103030B (zh) 2010-10-13

Family

ID=34864831

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2005800114336A Expired - Fee Related CN101103030B (zh) 2004-02-14 2005-02-10 具有hm74a受体活性的药物
CN2010102007350A Expired - Fee Related CN101863888B (zh) 2004-02-14 2005-02-10 具有hm74a受体活性的药物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010102007350A Expired - Fee Related CN101863888B (zh) 2004-02-14 2005-02-10 具有hm74a受体活性的药物

Country Status (25)

Country Link
US (5) US7713982B2 (enExample)
EP (1) EP1781657B1 (enExample)
JP (2) JP5001012B2 (enExample)
KR (1) KR101100601B1 (enExample)
CN (2) CN101103030B (enExample)
AR (1) AR047669A1 (enExample)
AU (1) AU2005212816C1 (enExample)
BR (1) BRPI0507604A (enExample)
CA (1) CA2556073C (enExample)
CY (1) CY1114022T1 (enExample)
DK (1) DK1781657T3 (enExample)
ES (1) ES2406732T3 (enExample)
HR (1) HRP20130406T1 (enExample)
IL (1) IL177051A (enExample)
MA (1) MA28357A1 (enExample)
MY (1) MY148937A (enExample)
NO (1) NO337281B1 (enExample)
NZ (1) NZ548496A (enExample)
PE (1) PE20060317A1 (enExample)
PL (1) PL1781657T3 (enExample)
PT (1) PT1781657E (enExample)
SG (1) SG157242A1 (enExample)
SI (1) SI1781657T1 (enExample)
TW (1) TWI350289B (enExample)
WO (1) WO2005077950A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104892610A (zh) * 2015-05-27 2015-09-09 福建师范大学 一种8-酯基咖啡因衍生物的制备方法
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1230243E (pt) * 1999-11-12 2009-06-12 Biogen Idec Inc Policicloalquilpurinas como antagonistas dos receptores da adenosina
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
CN101103030B (zh) * 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 具有hm74a受体活性的药物
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1885726B1 (en) 2005-05-17 2016-12-14 Merck Sharp & Dohme Corp. Ortho-condensed 2-pyridinone derivatives as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
KR100955112B1 (ko) 2005-06-14 2010-04-28 에프. 호프만-라 로슈 아게 안트라닐산 유도체
SI1901731T1 (sl) 2005-06-28 2011-07-29 Merck Sharp & Dohme Niacin receptorski antagonisti, sestavki vsebujoäśi take spojine in postopki zdravljenja
JP2009504592A (ja) * 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
AU2007208478A1 (en) * 2006-01-20 2007-08-02 Schering Corpooration Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
DE602007006947D1 (de) 2006-05-23 2010-07-15 Hoffmann La Roche Pyridopyrimidinonderivate
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
AU2007260852B2 (en) * 2006-06-23 2013-01-10 Incyte Corporation Purinone derivatives as HM74a agonists
CN101466714B (zh) 2006-06-23 2013-02-06 英赛特股份有限公司 作为hm74a激动剂的嘌呤酮衍生物
MX2009010218A (es) * 2007-03-23 2009-10-19 Hoffmann La Roche Derivados de aza-piridopirimidinona.
AU2009324811B2 (en) * 2008-12-08 2013-01-24 Glaxosmithkline Llc Novel compounds
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
CN102276610B (zh) * 2011-05-04 2013-01-09 北京工业大学 N7-鸟嘌呤烷化物的制备方法
CN103360394B (zh) * 2013-07-29 2015-07-22 上海万巷制药有限公司 8-氯茶碱的制备方法
SI3251675T1 (sl) * 2015-01-30 2021-08-31 Shanton Pharma Pte. Ltd. Preprečevanje ali zdravljenje sečnokislinske ali protinske bolezni
CN105622610A (zh) * 2016-03-28 2016-06-01 浙江诚意药业股份有限公司 一种黄嘌呤化合物的制备方法
CN109661238B (zh) 2016-07-27 2023-07-25 哈里斯制药公司 治疗红细胞疾病的治疗组合
CN106632061B (zh) * 2016-11-23 2020-07-24 上海皓元医药股份有限公司 一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法
EP3568395A1 (de) 2017-01-10 2019-11-20 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
US20220380370A1 (en) * 2019-09-25 2022-12-01 Goldfinch Bio, Inc. Xanthine cb1 inhibitors
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用
AU2024229006A1 (en) * 2023-02-27 2025-09-18 Shanton Pharma Pte. Ltd. Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0389282A2 (en) * 1989-03-23 1990-09-26 BEECHAM - WUELFING GmbH & Co. KG Xanthinederivatives, process for their preparation and their pharmaceutical use
WO1992009203A1 (en) * 1990-11-21 1992-06-11 Smithkline Beecham Corporation Tnf inhibitors
WO1993016699A1 (en) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
WO1999020280A1 (en) * 1997-10-17 1999-04-29 Smithkline Beecham Corporation Novel use of compounds for anti-pruritic activity
WO2002084298A2 (en) * 2001-04-11 2002-10-24 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
US4847377A (en) * 1985-05-13 1989-07-11 Schering Corporation Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones
CA2112239C (en) 1992-03-04 2000-05-09 James A. Bianco Enantiomeric hydroxylated xanthine compounds
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US5804584A (en) 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US6693105B1 (en) * 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
WO1994024133A1 (en) 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
EP0746557A4 (en) * 1994-02-18 1997-05-02 Cell Therapeutics Inc INTRACELLULAR SIGNALING MEDIATORS
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
JP2002541258A (ja) 1999-04-09 2002-12-03 セル セラピューティクス インコーポレーテッド インターリューキン−１２シグナルを阻害するための治療用化合物及びその使用方法
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
NZ517546A (en) * 1999-08-31 2003-10-31 Univ Vanderbilt Selective antagonists of A2B adenosine receptors
US6855817B2 (en) * 2000-07-21 2005-02-15 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
FR2812482B1 (fr) * 2000-07-28 2003-01-24 Inside Technologies Dispositif electronique portable comprenant plusieurs circuits integres sans contact
US20020156122A1 (en) * 2000-09-19 2002-10-24 Novlmmune S.A. Statins (HMG-CoA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
SK286975B6 (sk) 2001-02-24 2009-08-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
CN101103030B (zh) 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 具有hm74a受体活性的药物
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
JP2009504592A (ja) 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
AU2009324811B2 (en) * 2008-12-08 2013-01-24 Glaxosmithkline Llc Novel compounds
US20110065676A1 (en) * 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0389282A2 (en) * 1989-03-23 1990-09-26 BEECHAM - WUELFING GmbH & Co. KG Xanthinederivatives, process for their preparation and their pharmaceutical use
WO1992009203A1 (en) * 1990-11-21 1992-06-11 Smithkline Beecham Corporation Tnf inhibitors
WO1993016699A1 (en) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
WO1999020280A1 (en) * 1997-10-17 1999-04-29 Smithkline Beecham Corporation Novel use of compounds for anti-pruritic activity
WO2002084298A2 (en) * 2001-04-11 2002-10-24 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Joanthan R. S. Arch et al.Inhibition of type 4 cyclic nucleotide phosphodiesteraseby8-chloroxanthines.Arch Pharm. Pharm. Med. Chem.329 4.1996,329(4),205-208.
Joanthan R. S. Arch et al.Inhibition of type 4 cyclic nucleotide phosphodiesteraseby8-chloroxanthines.Arch Pharm. Pharm. Med. Chem.329 4.1996,329(4),205-208. *
Kattus Albert A. et al.Diuretic activity of compounds related to xanthines,uracils,andtriazines as determined in dogs.Bulletin of the Johns Hopkins Hospital89.1951,891-8. *
Kenneth A. Jacboson et al.Effect of trifluoromethyl and other substituents onactivityofxanthines at adenosine receptors.J. Med. Chem.36 18.1993,36(18),2639-2644.
Kenneth A. Jacboson et al.Effect of trifluoromethyl and other substituents onactivityofxanthines at adenosine receptors.J. Med. Chem.36 18.1993,36(18),2639-2644. *
Smellie F. W. et al.Alkylxanthine: inhibition ofadenosine-elicitedaccumlationofcyclic AMP in brainphosphodiesterase activity.Life Sciences24 26.1979,24(26),2475-2481.
Smellie F. W. et al.Alkylxanthine: inhibition ofadenosine-elicitedaccumlationofcyclic AMP in brainphosphodiesterase activity.Life Sciences24 26.1979,24(26),2475-2481. *
T. Katsushima et al.Structure-activity relationships of8-cycloalkyl-1,3-adenosinereceptors.J. Med. Chem.33 1.1990,33(1),1906-1910.
T. Katsushima et al.Structure-activity relationships of8-cycloalkyl-1,3-adenosinereceptors.J. Med. Chem.33 1.1990,33(1),1906-1910. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104892610A (zh) * 2015-05-27 2015-09-09 福建师范大学 一种8-酯基咖啡因衍生物的制备方法
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用

Also Published As

Publication number Publication date
NZ548496A (en) 2010-02-26
JP2007522176A (ja) 2007-08-09
MA28357A1 (fr) 2006-12-01
NO337281B1 (no) 2016-02-29
AR047669A1 (es) 2006-02-01
CY1114022T1 (el) 2016-07-27
US20130150383A1 (en) 2013-06-13
DK1781657T3 (da) 2013-06-10
US20150080418A1 (en) 2015-03-19
CN101103030A (zh) 2008-01-09
HK1104530A1 (en) 2008-01-18
EP1781657B1 (en) 2013-03-27
US8394808B2 (en) 2013-03-12
PT1781657E (pt) 2013-05-23
US20100160354A1 (en) 2010-06-24
JP2008120831A (ja) 2008-05-29
CA2556073A1 (en) 2005-08-25
US20100010021A1 (en) 2010-01-14
SI1781657T1 (sl) 2013-07-31
JP5001012B2 (ja) 2012-08-15
IL177051A0 (en) 2006-12-10
CA2556073C (en) 2012-01-10
ES2406732T3 (es) 2013-06-07
BRPI0507604A (pt) 2007-07-03
TWI350289B (en) 2011-10-11
US8268839B2 (en) 2012-09-18
IL177051A (en) 2013-01-31
TW200536537A (en) 2005-11-16
AU2005212816A1 (en) 2005-08-25
NO20064151L (no) 2006-11-06
HRP20130406T1 (hr) 2013-06-30
WO2005077950A2 (en) 2005-08-25
AU2005212816B2 (en) 2009-07-23
SG157242A1 (en) 2009-12-29
WO2005077950A3 (en) 2007-04-19
AU2005212816C1 (en) 2010-03-04
US20070135456A1 (en) 2007-06-14
PE20060317A1 (es) 2006-06-22
JP5020848B2 (ja) 2012-09-05
US7713982B2 (en) 2010-05-11
CN101863888B (zh) 2012-07-18
KR20060126772A (ko) 2006-12-08
KR101100601B1 (ko) 2011-12-29
MY148937A (en) 2013-06-14
PL1781657T3 (pl) 2013-08-30
CN101863888A (zh) 2010-10-20
EP1781657A2 (en) 2007-05-09

Similar Documents

Publication Publication Date Title
CN101103030B (zh) 具有hm74a受体活性的药物
CA2584904A1 (en) Xanthine derivatives with hm74a receptor activity
KR20080034993A (ko) 선택적 ｈｍ７４ａ 작동제로서의 크산틴 유도체
JP2009504593A (ja) 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
US20080221108A1 (en) Anthranilic Acid Derivatives As Hm74A Receptor Agonists
CN101274934A (zh) 具有hm74a受体活性的药物
RU2395511C2 (ru) Новые соединения
CN101087790A (zh) 具有hm74a受体活性的黄嘌呤衍生物
US20090209561A1 (en) Xanthine Derivatives with HM74A Receptor Activity
US5756735A (en) Xanthine derivatives
ES2354723T3 (es) Derivados de xantina como agonistas selectivos de hm74a.
HK1104530B (en) Medicaments with hm74a receptor activity
MXPA06009269A (en) Novel compounds
JP2002161100A (ja) ４−アルコキシ−２，３，６−トリメチルフェニルマンノシド類及びこれを含有する医薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101013

Termination date: 20200210

CF01 Termination of patent right due to non-payment of annual fee